Cell therapy using natural killer cells pretreatment with Anti-NKG2A in patients with hepatocellular carcinoma

Tehran University of Medical Sciences0 个研究点目标入组 3 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•Age of people between 20 and 60 years- Patients receiving the same chemotherapy regimen. Patients who have almost the same tumor size. Diffuse-form in terms of histopathology. Laboratory criteria for the proper functioning of vital organs in the form of:Liver function:Child-pugh A/Bserum aspartate aminotransferase (AST) =100 IU/Lalanine aminotransferase (ALT) =100 IU/Lserum total bilirubin =2 mg/dLRenal function: =1.5 mg/dL serum creatinineCardiac function: Absence of heart enzyme and ECG abnormalities, the survival expectancy is more than 6 months.leukocyte count =3000/mm3neutrophil count =1500/mm3platelet count =100,000/mm3hemoglobin =9.0 g/dLblood urea nitrogen level =25 mg/dL- All patients with active hepatitis B or C were treated with appropriate drugs and treated with targeted drugs.- Women must not be lactating or pregnant, must have a negative serum human chorionic gonadotropin B (HCG) test within 7 days prior to transplant day, and must agree to use an acceptable and reliable method of contraception during the study.- Have not undergone a liver transplant before.- All patients and donors sign an informed consent form.

•Pregnant or lactating women- People with hepatitis A, hepatitis E, AIDS or other infectious diseases- Patients with serious complications such as acute infection and gastrointestinal bleeding within 30 days- Patients with other serious systemic and psychiatric diseases- Having a history of autoimmune diseases and hypersensitivity- History of receiving any type of cell therapy in the last 6 months- Simultaneous participation in another clinical trial- Diseases such as diabetes mellitus, unstable angina or myocardial infarction within 3 months

发起方